• Life sciences M&A update: H1-2017

    Baker Tilly Capital, LLC's life sciences M&A newsletter provides an overview of the U.S. medical devices and products, pharmaceutical (pharma) and pharma outsourced services sectors, including recent performance and M&A trends.
  • Great Lakes regional M&A update: Q2-2017

    Middle-market M&A transactions in the Great Lakes region experienced a decrease in the total amount of deal volume, but an increase in aggregate deal value during the second quarter of 2017.
  • Overcoming the experimental or investigational label

    It is critical for a medical device company to quickly develop a strategy to generate a comprehensive body of evidence to reverse negative coverage decisions if a medical technology has already been classified as experimental or investigational. Learn more about developing the strategy.